Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
1(33.3%)
N/A
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 1(1)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06815432Phase 1Recruiting

GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma

Role: collaborator

NCT06686043Phase 2Recruiting

HPV Vaccine, Imiquimod, and Metformin Combination Trial

Role: collaborator

NCT05957588Not ApplicableCompleted

Non-ventilated Prone Positioning in the COVID-19 Population

Role: lead

NCT05147389Completed

Artificial Intelligence for Digital Cholangioscopy Neoplasia Diagnosis

Role: collaborator

All 4 trials loaded